Voices
Karamvir Yadav: Would You Add Immunotherapy Upfront to Prevent Chemotherapy Resistance?
Karamvir Yadav/X

Karamvir Yadav: Would You Add Immunotherapy Upfront to Prevent Chemotherapy Resistance?

Karamvir Yadav, Medical Oncologist at Harish Renova Hospital, shared a post on X:

“Would you add immunotherapy upfront to prevent chemotherapy resistance?

The TROPHAMET trial reports a 96.2% durable remission rate and no relapses at 41 months with avelumab + methotrexate in low-risk GTT. Rare disease.

Big signal. Worth watching closely.”

Karamvir Yadav

Title: Avelumab Plus Methotrexate for Gestational Trophoblastic Tumors

Authors: Benoit You, Jean-Pierre Lotz, Pierre Descargues, Florence Joly, Thibault De La Motte Rouge, Coriolan Lebreton, Laurence Gladieff, Philippe Follana, Mathieu Jamelot, Jerome Massardier, Touria Hajri, Adrien Msika, Marine Alves-Ferreira, Sylvie Bin, Carole Langlois-Jacques, Fabien Subtil, Adeline Roux, Christophe Desauw, Magali Provansal, Verane Schwiertz, Francois Golfier, Pierre-Adrien Bolze

Read The Full Article

Karamvir Yadav

Other articles about Immunotherapy on OncoDaily.

Adeline Roux Adrien Msika Benoit You cancer Carole Langlois-Jacques Christophe Desauw Coriolan Lebreton Fabien Subtil Florence Joly Francois Golfier Jean-Pierre Lotz Jerome Massardier Karamvir Yadav Laurence Gladieff Magali Provansal Marine Alves-Ferreira Mathieu Jamelot OncoDaily Oncology Philippe Follana Pierre Descargues Pierre-Adrien Bolze Sylvie Bin Thibault de la Motte Rouge Touria Hajri Verane Schwiertz